Genmab A/S (GMAB) reported positive results from its clinical trial for Epkinly (epcoritamab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This is a significant development for the company, as Epkinly is a bispecific antibody developed in collaboration with AbbVie and is already approved for other indications.

The positive trial results could expand Epkinly's addressable market and solidify its position in the competitive oncology landscape. The drug's efficacy in DLBCL, a challenging cancer to treat, suggests a strong commercial opportunity.

Now, the market is evaluating whether GMAB's stock price, which currently reflects a company with $21.5B in revenue and 30.7% YoY growth, has fully priced in the potential sales boost and improved outlook from this expanded indication. The question is whether the market has adequately discounted the future revenue streams and profit margins (currently 36.4% net) that Epkinly could generate in this new segment.

Traders will be watching for analyst updates and management commentary on the regulatory path and commercialization strategy for Epkinly in DLBCL. The stock's performance will likely hinge on how quickly and effectively Genmab can translate these positive trial results into market share and revenue growth, especially considering its current P/E multiple relative to peers and growth prospects.